Literature DB >> 16538239

Investigation of the medium-term effects of Olibratrade mark fat emulsion on food intake in non-obese subjects.

C M Logan1, T A McCaffrey, J M W Wallace, P J Robson, R W Welch, A Dunne, M B E Livingstone.   

Abstract

OBJECTIVE: To investigate the effect of Olibra fat emulsion on medium-term food intake and appetite in non-obese subjects.
DESIGN: Double-blind, placebo-controlled, within-subject crossover.
SETTING: University of Ulster, Coleraine.
SUBJECTS: A total of 28 subjects (14 male, 14 female).
INTERVENTIONS: Subjects were randomly assigned to receive either a 200 g portion of test (5 g of Olibra fat) or control (5 g milk fat) yoghurt for breakfast for 2 x 3 week 'study' phases, separated by a 3-week 'wash-out' phase. On days 1, 8 and 22 of the study phases, food intake 4 h post-consumption of the yoghurt was assessed by pre- and post-covert weighing at an ad libitum buffet-style test lunch. Throughout each of these study days, appetite was assessed using visual analogue scales (VAS) at regular intervals. For the remainder of the study days, and the following 24 h ('post-study days'), subjects reported their food intake using weighed dietary records.
RESULTS: Consumption of the Olibra emulsion had no significant effect on mean energy, macronutrient or amounts of food consumed at the lunch 4 h post-consumption. Self-reported food intakes indicated that there was no significant effect of the emulsion on energy intakes for the remainder of each study day and post-study days. There was considerable individual variation in food intakes following consumption of the Olibra emulsion, with 46, 59 and 57% of subjects reducing their energy intakes at lunch on days 1, 8 and 22. There was no consistent effect of the emulsion on appetite ratings.
CONCLUSIONS: In contrast to earlier studies, there was no evidence of a short- or medium-term effect of the Olibra emulsion on food intake or appetite. This could be owing to numerous confounding factors influencing eating behaviour and/or the different study design used in the present study. Published online 15 March 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16538239     DOI: 10.1038/sj.ejcn.1602422

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  6 in total

Review 1.  Efficacy of Olibra: a 12-week randomized controlled trial and a review of earlier studies.

Authors:  Candida J Rebello; Corby K Martin; William D Johnson; Carol E O'Neil; Frank L Greenway
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

2.  An analysis of the "Effect of Olibra: a 12-week randomized control trial and a review of earlier studies".

Authors:  Martina Heer
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

3.  Effect of a vegetable-oil emulsion on body composition; a 12-week study in overweight women on a meal replacement therapy after an initial weight loss: a randomized controlled trial.

Authors:  Johan Olsson; Birgitta Sundberg; Annika Viberg; Arvo Haenni
Journal:  Eur J Nutr       Date:  2010-09-07       Impact factor: 5.614

4.  Postprandial effects on plasma lipids and satiety hormones from intake of liposomes made from fractionated oat oil: two randomized crossover studies.

Authors:  Lena Ohlsson; Anna Rosenquist; Jens F Rehfeld; Magnus Härröd
Journal:  Food Nutr Res       Date:  2014-10-06       Impact factor: 3.894

Review 5.  The scale of the evidence base on the health effects of conventional yogurt consumption: findings of a scoping review.

Authors:  Julie M Glanville; Sam Brown; Raanan Shamir; Hania Szajewska; Jacqualyn F Eales
Journal:  Front Pharmacol       Date:  2015-10-30       Impact factor: 5.810

6.  The Effect of an Encapsulated Nutrient Mixture on Food Intake and Satiety: A Double-Blind Randomized Cross-Over Proof of Concept Study.

Authors:  Annick M E Alleleyn; Mark van Avesaat; Dina Ripken; Sinéad B Bleiel; Daniel Keszthelyi; Ellen Wilms; Freddy J Troost; Henk F J Hendriks; Adrian A M Masclee
Journal:  Nutrients       Date:  2018-11-17       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.